CN101827604B - 焦虑治疗 - Google Patents

焦虑治疗 Download PDF

Info

Publication number
CN101827604B
CN101827604B CN200880104999.7A CN200880104999A CN101827604B CN 101827604 B CN101827604 B CN 101827604B CN 200880104999 A CN200880104999 A CN 200880104999A CN 101827604 B CN101827604 B CN 101827604B
Authority
CN
China
Prior art keywords
anxiety
patient
arg
xaa
prt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880104999.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN101827604A (zh
Inventor
A·塔斯克
T·杜塞特
M·蒂米安斯基
K·门多萨
M·P·贝尔马里斯
D·加曼
P·S·卢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NoNO Inc
Original Assignee
NoNO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NoNO Inc filed Critical NoNO Inc
Publication of CN101827604A publication Critical patent/CN101827604A/zh
Application granted granted Critical
Publication of CN101827604B publication Critical patent/CN101827604B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200880104999.7A 2007-07-03 2008-07-02 焦虑治疗 Expired - Fee Related CN101827604B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94789207P 2007-07-03 2007-07-03
US60/947,892 2007-07-03
PCT/US2008/069085 WO2009006548A2 (en) 2007-07-03 2008-07-02 Treatment for anxiety

Publications (2)

Publication Number Publication Date
CN101827604A CN101827604A (zh) 2010-09-08
CN101827604B true CN101827604B (zh) 2014-05-07

Family

ID=40226818

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880104999.7A Expired - Fee Related CN101827604B (zh) 2007-07-03 2008-07-02 焦虑治疗

Country Status (10)

Country Link
US (2) US8008253B2 (enExample)
EP (1) EP2175873B1 (enExample)
JP (2) JP5775303B2 (enExample)
KR (1) KR101604428B1 (enExample)
CN (1) CN101827604B (enExample)
AU (1) AU2008272903B2 (enExample)
CA (1) CA2692412C (enExample)
DK (1) DK2175873T3 (enExample)
ES (1) ES2555172T3 (enExample)
WO (1) WO2009006548A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
JP6005357B2 (ja) * 2008-05-16 2016-10-12 ノノ インコーポレイテッド てんかんの治療
AU2009288088B2 (en) * 2008-09-03 2014-12-04 Nono Inc. Agents and methods for treatment of pain
WO2013163562A2 (en) * 2012-04-27 2013-10-31 Indiana University Research And Technology Corporation Compositions and methods for treating ptsd and related diseases
CN105705605B (zh) 2013-11-05 2018-07-31 三菱化学株式会社 粘合剂组合物
CN106104658B (zh) 2014-03-10 2019-11-29 三菱化学株式会社 图像显示装置构成用层叠体的制造方法
KR102605540B1 (ko) * 2014-05-28 2023-11-22 노노 인코포레이티드 Tat-nr2b9c의 클로라이드 염
WO2017093354A1 (en) 2015-11-30 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Nmdar antagonists for the treatment of diseases associated with angiogenesis
WO2017138544A1 (ja) 2016-02-08 2017-08-17 三菱ケミカル株式会社 透明両面粘着シート及び粘着シート積層体
KR102652894B1 (ko) 2016-02-08 2024-04-01 미쯔비시 케미컬 주식회사 투명 양면 점착 시트 및 점착 시트 적층체
ES2869300T3 (es) * 2016-04-27 2021-10-25 Biocells Beijing Biotech Co Ltd Péptido terapéutico para las lesiones relacionadas con la neurotoxicidad excitadora
CN107312069B (zh) * 2016-04-27 2018-11-06 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗肽
CN106632601B (zh) * 2016-11-16 2020-10-20 中国科学院昆明动物研究所 一种阻断突触长时程增强（ltp）的短肽及其应用
EA039314B1 (ru) * 2017-07-05 2022-01-12 Биоселз (Бейдзин) Биотек Ко., Лтд. Фармацевтически приемлемые соли полипептидов и их применение
WO2019061395A1 (zh) * 2017-09-30 2019-04-04 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗肽组合物
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
TW202132325A (zh) * 2019-11-05 2021-09-01 國立大學法人京都大學 胜肽、組成物以及治療、預防或改善情緒障礙之方法
CN111285923B (zh) * 2020-03-05 2023-02-03 成都奥达生物科技有限公司 一种psd-95抑制剂
CN113735938B (zh) 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723838B1 (en) * 1998-04-22 2004-04-20 Johns Hopkins University Signal transducing synaptic molecules and uses thereof
CN1747735A (zh) * 2003-02-17 2006-03-15 诺瓦提斯公司 S－10－羟基－10,11－二氢－卡马西平在治疗焦虑和双相情感障碍中的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148711A1 (en) * 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US6942981B1 (en) * 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
WO2002000629A1 (en) 2000-06-26 2002-01-03 Merck & Co., Inc. Iminopyrimidine nmda nr2b receptor antagonists
WO2004045535A2 (en) 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
FI20012082A0 (fi) * 2001-10-26 2001-10-26 Paeivi Liesi Biologisesti aktiiviset peptidit hermovauroiden korjaamiseksi
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
WO2005017203A2 (en) * 2003-07-11 2005-02-24 Yale University Systems and methods for diagnosing and treating psychological and behavioral conditions
AU2004289290A1 (en) * 2003-11-12 2005-05-26 Merck & Co., Inc. 4-phenyl piperdine sulfonyl glycine transporter inhibitors
HU226977B1 (en) * 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
US20060167075A1 (en) * 2005-01-25 2006-07-27 Pearson James P Modulators of FAAH
US20060216331A1 (en) * 2005-02-28 2006-09-28 Lines Thomas C Composition for treating mental health disorders
WO2007002395A1 (en) * 2005-06-23 2007-01-04 Arbor Vita Corporation Methods and compositions for modulating cox
KR101384572B1 (ko) * 2005-12-30 2014-04-24 아버 비타 코포레이션 Ｐｄｚ 상호작용의 소형 분자 억제제
US8262847B2 (en) * 2006-12-29 2012-09-11 Lam Research Corporation Plasma-enhanced substrate processing method and apparatus
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723838B1 (en) * 1998-04-22 2004-04-20 Johns Hopkins University Signal transducing synaptic molecules and uses thereof
CN1747735A (zh) * 2003-02-17 2006-03-15 诺瓦提斯公司 S－10－羟基－10,11－二氢－卡马西平在治疗焦虑和双相情感障碍中的用途

Also Published As

Publication number Publication date
CA2692412A1 (en) 2009-01-08
WO2009006548A2 (en) 2009-01-08
US8536129B2 (en) 2013-09-17
JP5775303B2 (ja) 2015-09-09
KR20100038366A (ko) 2010-04-14
US20120083449A1 (en) 2012-04-05
CA2692412C (en) 2017-02-07
WO2009006548A3 (en) 2009-03-19
EP2175873B1 (en) 2015-11-11
AU2008272903A1 (en) 2009-01-08
KR101604428B1 (ko) 2016-03-17
EP2175873A4 (en) 2011-10-05
ES2555172T3 (es) 2015-12-29
JP2010532761A (ja) 2010-10-14
AU2008272903B2 (en) 2013-08-29
CN101827604A (zh) 2010-09-08
US8008253B2 (en) 2011-08-30
US20090036376A1 (en) 2009-02-05
JP2014129353A (ja) 2014-07-10
EP2175873A2 (en) 2010-04-21
AU2008272903A8 (en) 2010-05-06
DK2175873T3 (en) 2015-12-14

Similar Documents

Publication Publication Date Title
CN101827604B (zh) 焦虑治疗
US9161965B2 (en) Treatment for epilepsy
Profyris et al. Degenerative and regenerative mechanisms governing spinal cord injury
CA2657665C (en) Method and compositions for treating stroke with fever
CN103282379A (zh) Nd2肽和神经疾病的治疗方法
Donev Ion Channels as Therapeutic Targets, Part B

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Free format text: FORMER OWNER: ARBOR VITA CORP;NONO INC.

Effective date: 20130326

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130326

Address after: Ontario

Applicant after: NoNO Inc.

Address before: Ontario

Applicant before: NoNo Inc.

Applicant before: Arbor Vita Corp.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140507

CF01 Termination of patent right due to non-payment of annual fee